"Plicamycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricyclic pentaglycosidic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA. It is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies.
| Descriptor ID |
D008926
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.650 D04.615.562.050.650 D09.408.051.059.650
|
| Concept/Terms |
Plicamycin- Plicamycin
- Mitramycin
- Aureolic Acid
- Acid, Aureolic
- Mithramycin
|
Below are MeSH descriptors whose meaning is more general than "Plicamycin".
Below are MeSH descriptors whose meaning is more specific than "Plicamycin".
This graph shows the total number of publications written about "Plicamycin" by people in this website by year, and whether "Plicamycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Plicamycin" by people in Profiles.
-
Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell. 2014 Jul 14; 26(1):33-47.
-
Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 2011 Aug 01; 71(15):5182-93.
-
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30.
-
Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol. 2010 Apr; 30(8):1866-77.
-
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010 Feb 01; 70(3):1111-9.
-
Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol. 2008 Jul; 33(1):161-7.
-
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007 Dec 15; 110(12):2682-90.
-
Transcriptional control of human T-BET expression: the role of Sp1. Eur J Immunol. 2007 Sep; 37(9):2549-61.
-
Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007 May 15; 67(10):4878-85.
-
Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1. J Biol Chem. 2002 May 10; 277(19):16673-81.